Tim Smith

In this interview at AAD 2024, Porter discusses recent data from the SUNSHINE and SUNRISE trials on secukinumab for patients with HS.

In late-breaking data from AAD 2024, treatment with the JNJ-2113 targeted oral peptide led to several notable findings regarding patients with moderate-to-severe psoriasis.

Hamzavi discusses new late-breaking data from AAD 2024, including major takeaways and safety profile after 52 weeks.

These findings from AAD 2024 did not include statistically significant infliximab response predictors, though it had been the largest reported cohort on the subject to date.

In this new analysis presented at AAD 2024, patients with HS saw substantial improvements in their hidradenitis suppurativa-related pain following treatment with bimekizumab.

A new analysis of the phase 3 ADORING 3 extension trial involved a large, diverse population and the analysis showed that 91% of eligible participants from previous phases rolled over into this trial.

In phase 4 data from the IMMpulse study, presented at AAD 2024, comparisons in efficacy were highlighted between risankizumab and apremilast for psoriasis patients eligible for systemic therapy.

In this discussion, Jonathan Silverberg described his team’s new phase 3 findings presented at AAD 2024 regarding upadacitinib and its impact on minimal disease activity in eczema patients.

These data suggest that, among children with atopic dermatitis and ADHD or other learning disabilities, an assessment for impairment of their cognitive abilities may need prioritization.

This analysis concluded that the carcinogen known as benzene can be broadly found in concerning levels within benzoyl peroxide (BPO) acne treatment products.

This analysis was conducted to address previous suspicions on the results of pulse oximetry among patients with skin of color.

These mental health outcomes were seen among those with self-reported COPD and asthma, though not among individuals with objective diagnoses based on spirometry.

This analysis looked into whether rapid respiratory virus testing in patients with suspected acute respiratory infection was linked to such outcomes as antibiotic use decrease and hospitalization.

This is the first instance in which a patient without a response to sequential bronchial thermoplasty, dupilumab, benralizumab, and mepolizumab ended up with a strong clinical response to tezepelumab.

This analysis explored views on safety, general levels of trust, and preferences on examination methods, with the goal being a greater awareness of opinion on AI incorporation.

These data suggest the potential for use of patient-reported outcomes in terms of risk stratification and selection of treatment for patients in both clinical practice and other studies.

In the February edition of Dermatology Month in Review, new acne guidelines released by AAD, an FDA decision on nemolizumab, and an interview on potentially the first oral IL-23 inhibitor for psoriasis were among the major stories.

These findings suggest much lower prices can be achieved for medications, with better alignment to the benefits of different biological psoriasis treatments.

In honor of Rare Disease Day, this exploration of prurigo nodularis highlights the skin disease’s psychosocial impact on patients around the world living with the condition.

This analysis presented at AAAAI suggests that the experimental OMIT delivery of allergens via toothpaste may allow for a safer alternative to other immunotherapies.

This announcement by UCB follows the results of four phase 3 studies on the use of bimekizumab for PsA, ankylosing spondylitis, and non-radiographic axial spondyloarthritis.

This analysis emphasizes the necessity of prevention of melanoma as well as the public health and economic consequences of patients’ delaying of skin cancer diagnoses.

In this Q&A discussion, Bhatt discusses the recent news of dupilumab’s supplemental Biologics License Application for COPD patients with type 2 inflammation, as well as its significance.

These new data from BioCryst, presented at AAAAI, suggest that patients treated with berotralstat may see substantial decreases in HAE attacks.

Twelve evidence-based Key Action Statements were provided for clinicians to guide them in the treatment of patients reporting inhalant allergy symptoms.

In an interview during the 2024 AAAAI conference, Casale addressed his team’s findings regarding epinephrine nasal spray and its effectiveness with regard to exacerbations of urticaria.

These findings may allow for patients with severe allergic reactions to have an alternative to epinephrine auto-injector devices.

In this interview, Ebisawa discusses his team’s recent research into the frequently-discussed non-injector epinephrine alternative neffy.

These findings, to be presented at AAAAI, may help to expand upon clinicians’ awareness of the mechanics of air pollution’s effect on asthma.

The FDA’s decision is planned for June 2024, and follows the successful results of the BOREAS and NOTUS trials.